Novozymes’ biopharma-sales cut in half
In 2012 the biopharma-division in the Danish company Novozymes only produced half the turnover it managed the year before. Read on to see why.
by Stefan Singh Kailay
From 254 million kroner (USD 45 million) to 127 million kroner (USD 22.5 million) in 2012, a decline of exactly 50 % - those are the raw facts for Novozymes’ biopharma-division.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
